Compare WLTH & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WLTH | ATAI |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | 391 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 2025 |
| Metric | WLTH | ATAI |
|---|---|---|
| Price | $8.44 | $4.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $12.86 | ★ $15.88 |
| AVG Volume (30 Days) | 2.1M | ★ 5.0M |
| Earning Date | 05-18-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | $10.58 | N/A |
| Revenue Next Year | $23.43 | N/A |
| P/E Ratio | $10.57 | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $7.20 | $2.00 |
| 52 Week High | $14.12 | $6.73 |
| Indicator | WLTH | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 28.40 | 48.20 |
| Support Level | $8.29 | $4.00 |
| Resistance Level | $9.32 | $4.20 |
| Average True Range (ATR) | 0.62 | 0.33 |
| MACD | -0.26 | -0.02 |
| Stochastic Oscillator | 8.61 | 29.20 |
Wealthfront Corp is a product-driven technology company that built a financial solutions platform for digital natives. The platform is designed to address the needs of the wealth builders within these generations. Its business model is designed to optimize for clients' success. The focus on delivering fully automated services results in being one of the lowest cost producers in each category in which participate. The group generates revenue from cash management and investment advisory products. Cash management revenue is earned from fees received for the delivery of cash management services, including the cash sweep program.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.